Tofidence for Autoimmune Diseases FDA approved Tofidence (tocilizumab-bavi) as biosimilar to U.S.-licensed Actemra (tocilizumab) . This product is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. Tofidence is approved for the following indications currently approved for U.S.-licensed Actemra: Rheumatoid
Prescription medication spend is a steadily increasing share of overall healthcare cost. Over the past 15 years, some health plans have seen spend on drugs grow from 10% to 25% of total expenditures per year. These costs aren’t driven by the quantity of drugs that beneficiaries are taking now.
The landscape of rheumatological treatments has witnessed significant advancements in the past few decades. One notable milestone is the introduction of biosimilars, which have the potential to revolutionize the approach to managing a myriad of rheumatologic conditions. But what exactly are biosimilars, and how do they fare in terms of
Biologic infusions offer highly specialized and targeted treatments for many rheumatologic conditions. Historically, such treatments were confined to hospitals or infusion centers, which increase patient handoffs and cost of care. In-office infusion centers have many advantages for providers and their patients. They offer patients flexibility and convenience but also ensure
In response to surging inflation rates, the Biden Administration introduced the Inflation Reduction Act (IRA)1, a legislation targeting not just healthcare but also the energy, manufacturing, and transportation sectors. The Act demands that major health programs such as Medicare Advantage Part D, the Affordable Care Act (ACA), Medicaid, and
Despite over 50 years of evidence and numerous studies, hyaluronic acid injections for knee osteoarthritis show minimal benefit over placebos, draining significant resources from the American healthcare system. The expenditures surpass a staggering $400 million annually in Medicare claims in 2019 with an estimated one in seven patients with osteoarthritic
By Andrew Ninh In the realm of U.S. healthcare, the arrival of Semaglutide and other GLP-1s has triggered a cascade of responses among varied stakeholders. These drugs present a game-changer in treating diabetes and obesity, requiring a detailed exploration of their implications on diverse health plans and risk-bearing entities,
As 2023 draws to a close, the world of pharmaceuticals is abuzz with the transformative potential of biosimilars. Unlike traditional generic drugs, which are exact replicas of small-molecule branded medications, biosimilars are near-copies of complex biologic drugs produced by different manufacturers. The burgeoning biosimilar market in the U.S. is
Biologics are here to stay. With 60% of current pipeline therapies falling into the infused or injected category, this niche of medicine is not going away. From asthma and allergy to migraines and gout, Crohn’s, and everything in between, there are few chronic disease states not touched by biologics.
The U.S. Food and Drug Administration (FDA) has announced its approval for the innovative drug, Veopoz (pozelimab-bbfg) [1,2], making it the inaugural approved remedy for CHAPLE disease, which affects both adults and children over one year of age. What is CHAPLE Disease? CHAPLE , an acronym for complement
What are Biosimilars? A biosimilar is a type of biologic drug that are highly similar to an already approved reference biologic. These drugs are developed to have no meaningful differences in terms of safety, efficacy, and quality when compared to the reference biologic . Biosimilars have the potential to offer
Hello and welcome to CuraFi's inaugural blog post! At the heart of Silicon Valley, we are sculpting the future of healthcare by revolutionizing the way society addresses the financial challenges of high-cost therapeutics. In an age where groundbreaking treatments often come with multi-million dollar price tags, it's essential to innovate